review Open AccessTop 1% cited
Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Diabetologia · 2022 · Vol. 65(12) · pp. 1925–1966
Melanie J. Davies✉(University of Leicester)Vanita R. Aroda(Brigham and Women's Hospital)Billy S. Collins(National Heart Lung and Blood Institute)Robert A. Gabbay(Ada Technologies (United States))Jennifer Green(Duke University)Nisa M. Maruthur(Johns Hopkins University)Sylvia E. Rosas(Joslin Diabetes Center)Stefano Del Prato(University of Pisa)Chantal Mathieu(KU Leuven)Geltrude Mingrone(Università Cattolica del Sacro Cuore)Peter Rossing(University of Copenhagen)Tsvetalina Tankova(Medical University of Sofia)Απόστολος Τσάπας(Aristotle University of Thessaloniki)John B. Buse✉(University of North Carolina at Chapel Hill)
Diabetes Treatment and ManagementDiabetes Management and ResearchMetabolism, Diabetes, and CancerDiabetes mellitusMedicineType 2 diabetesHuman physiologyAssociation (psychology)Internal medicineEndocrinologyPsychology
MeSH terms
Glucagon-Like Peptide-1 ReceptorSodium-Glucose Transporter 2 InhibitorsGlucagon-Like Peptide-1 Receptor AgonistsAdultDiabetes Mellitus, Type 2HumansHyperglycemiaHypoglycemic AgentsUnited StatesConsensus
Funding
- American Diabetes Association
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Sanofi
- Gilead Sciences
- Ohio State University
- Medpace
- Johns Hopkins University
- University Hospitals of Leicester NHS Trust
- Insulet Corporation
- ReCor Medical
- Dexcom
- Moderna
- University of Leicester
- University of Southampton
- Newcastle University
- European Foundation for the Study of Diabetes
- Daewoo Shipbuilding & Marine Engineering
- KU Leuven
- Novo Nordisk
- Sapienza Università di Roma
- Astellas Pharma
- Universitat de Barcelona
- Aristotle University of Thessaloniki
- European Association for the Study of Diabetes
- Servier
- University of North Carolina at Chapel Hill
- Takeda Pharmaceuticals International
Citations
928
FWCI
118.44
field-weighted impact
References
353
Percentile
100%
vs. same field & year
Citations per year
References
Decision aids for people facing health treatment or screening decisions
Cochrane Database of Systematic Reviews · 2017 · 6,580 citations
Mortality and causes of death in the WHO multinational study of vascular disease in diabetes
Diabetologia · 2001 · 1,290 citations
Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes
Diabetologia · 2015 · 688 citations
GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations
Journal of Clinical Epidemiology · 2013 · 1,378 citations
Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Diabetologia · 2012 · 3,930 citations
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
New England Journal of Medicine · 2015 · 11,756 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.